ADJUVANT PAZOPANIB OR PLACEBO IN RESECTED STAGE I NSCLC PATIENTS: RESULTS OF THE NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-0703) FROM THE FRENCH COLLABORATIVE INTERGROUP

被引：0
|
作者：
Besse, Benjamin [1 ]
Mazieres, Julien [2 ]
Ribassin-Majed, L. [3 ]
Barlesi, Fabrice [4 ]
Bennouna, Jaafar [5 ]
Gervais, Radj [6 ]
Moreau, Lionel
Berard, Henri [7 ]
Debieuvre, Didier
Molinier, Olivier [8 ]
Moro-Sibilot, Denis [9 ]
Souquet, Pierre-Jean [10 ]
Pignon, Jean-Pierre [3 ]
Amour, Elodie [11 ]
Celebic, A. [3 ]
Morin, Franck [11 ]
Milleron, Bernard [11 ]
Zalcman, Gerard [12 ]
Soria, Jean-Charles [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Univ Toulouse 3, Resp Med Serv, Hop Larrey, Chu Toulouse, F-31062 Toulouse, France
[3] Gustave Roussy, Biostat, Villejuif, France
[4] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France
[5] Inst Cancerol Ouest, Gustave Roussy, France
[6] Ctr Francois Baclesse, Caen, France
[7] Hop Instruct Armees St Anne, Serv Pathol Resp, Toulon, France
[8] Le Mans Reg Hosp, Le Mans, France
[9] Unite Oncol Thorac Pneumol, Pierre Benite, France
[10] Pneumol Hcl, Paris, France
[11] Ifct, Paris, France
[12] Caen Univ Hosp, Caen, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
adjuvant; Non small cell lung cancer; angiogenic inhibitor; randomized phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO08.02
引用
收藏
页码：S301 / S301
页数：1
相关论文
共 39 条
  • [31] IFCT-0803 TRIAL: A PHASE II STUDY OF CETUXIMAB, PEMETREXED, CISPLATIN AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III, NON SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY SAFETY ANALYSIS
    Tredaniel, Jean
    Mornex, Francoise
    Barlesi, Fabrice
    Le Pechoux, Cecile
    Pichon, Eric
    Lerouge, Delphine
    Le Moulec, Sylvestre
    Westeel, Virginie
    Moreau, Lionel
    Petit, Lidia
    Friard, Sylvie
    Baudrin, Laurence
    Lebitasy, Marie Paule
    Zalcman, Gerard
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1154 - S1155
  • [32] High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
    Zwierenga, Fenneke
    van Veggel, Bianca
    Hendriks, Lizza E. L.
    Hiltermann, T. Jeroen N.
    Hiddinga, Birgitta I.
    Kappelle, Lucie B. M. Hijmering
    ter Elst, Arja
    Hashemi, Sayed M. S.
    Dingemans, Anne-Marie C.
    van der Leest, Cor
    de Langen, Adrianus J.
    van den Heuvel, Michel M.
    van der Wekken, Anthonie J.
    LUNG CANCER, 2022, 170 : 133 - 140
  • [33] Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)
    Lv, C.
    Wang, R.
    Li, S.
    Yan, S.
    Wang, Y.
    Chen, J.
    Wang, L.
    Liu, Y.
    Guo, Z.
    Wang, J.
    Pei, Y.
    Yu, L.
    Wu, N.
    Lu, F.
    Gao, F.
    Chen, J.
    Liu, Y.
    Wang, X.
    Li, S.
    Han, B.
    Zhang, L.
    Ma, Y.
    Ding, L.
    Wang, Y.
    Yuan, X.
    Yang, Y.
    ESMO OPEN, 2023, 8 (04)
  • [34] Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: results of a multicentre randomized phase II trial
    Binder, D.
    Schweisfurth, H.
    Grah, C.
    Schaeper, C.
    Temmesfeld-Wollbrueck, B.
    Siebert, G.
    Suttorp, N.
    Beinert, T.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 143 - 150
  • [35] Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial
    D. Binder
    H. Schweisfurth
    C. Grah
    C. Schäper
    B. Temmesfeld-Wollbrück
    G. Siebert
    N. Suttorp
    T. Beinert
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 143 - 150
  • [36] Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial
    Noriyasu Usami
    Kohei Yokoi
    Yoshinori Hasegawa
    Hiroyuki Taniguchi
    Joe Shindo
    Masashi Yamamoto
    Ryujiro Suzuki
    Kazuyoshi Imaizumi
    Masashi Kondo
    Kaoru Shimokata
    International Journal of Clinical Oncology, 2010, 15 : 583 - 587
  • [37] Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA-N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy
    Li, N.
    Zeng, Z. -F.
    Wang, S. -Y.
    Ou, W.
    Ye, X.
    Li, J.
    He, X. -H.
    Zhang, B. -B.
    Yang, H.
    Sun, H. -B.
    Fang, Q.
    Wang, B. -X.
    ANNALS OF ONCOLOGY, 2015, 26 (03) : 504 - 509
  • [38] Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial
    Usami, Noriyasu
    Yokoi, Kohei
    Hasegawa, Yoshinori
    Taniguchi, Hiroyuki
    Shindo, Joe
    Yamamoto, Masashi
    Suzuki, Ryujiro
    Imaizumi, Kazuyoshi
    Kondo, Masashi
    Shimokata, Kaoru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (06) : 583 - 587
  • [39] Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study
    Zeng, Jian
    Mao, Wei-Min
    Chen, Qi-Xun
    Luo, Tao-Bo
    Wu, Yi-Long
    Zhou, Qing
    Yang, Xue-Ning
    Yan, Hong-Hong
    Zhong, Wen-Zhao
    Wang, Qun
    Xu, Song-Tao
    Wu, Lin
    Shen, Yi
    Liu, Yong-Yu
    Chen, Chun
    Cheng, Ying
    Xu, Lin
    Wang, Jun
    Fei, Ke
    Li, Xiao-Fei
    Li, Jian
    Huang, Cheng
    Liu, Zhi-Dong
    Xu, Shun
    Chen, Ke-Neng
    Xu, Shi-Dong
    Liu, Lun-Xu
    Yu, Ping
    Wang, Bu-Hai
    Ma, Hai-Tao
    LUNG CANCER, 2020, 150 : 164 - 171
1234